American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

Medicaid money dollar reimbursement

Cardiology groups among the many voices asking Congress not to cut Medicaid

More than 40 U.S. healthcare organizations are urging Congress not to make sweeping Medicaid cuts that could result in approximately 7.6 million Americans losing health insurance.

Intravascular lithotripsy IVL carotid artery TAVR

A new use for IVL: helping cardiologists secure transcarotid access for TAVR

IVL can do more than help prep patients for PCI. In fact, one heart team used Shockwave Medical's IVL technology to secure access for a high-risk TAVR patient.

Dan Budoff explains use of CCTA to track coronary disease plaque progression

CCTA shows colchicine's impact on atherosclerosis progression

Matthew Budoff, MD, detailed new data highlighting CCTA's value when it comes to tracking the progression of coronary atherosclerosis.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward. 

HeartMate 3 LVAD abbott

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients

Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure

Philippe Genereux, MD, director of the structural heart program at Morristown Medical Center, principal investigator of the late-breaking EARLY TAVR trial, presented new data at ACC 2025 showing intervening earlier on patients with asymptomatic severe aortic stenosis leads to better outcomes.

Latest EARLY TAVR data suggest it is time to update industry guidelines

Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate. 

Thumbnail

PFA associated with elevated risk of heart damage, real-world data show

Patient outcomes do not appear to be negatively impacted by these risks, researchers noted. The new data were presented at Heart Rhythm 2025 and published in JACC: Clinical Electrophysiology.

doctor with overweight patient who may be treated with TAVR or surgery

Bayer's finerenone reduces risk of AFib, atrial flutter in all CKM syndrome patients

New data published in JACC represents another big win for Bayer's finerenone. The drug has previously been linked to cardiovascular benefits for patients with CKD and heart failure, but its potential across the full CKM spectrum remained a bit of a mystery.